Long-Term Follow-Up Study Monitoring Participants Previously Treated with TScan TCR-T Cell Therapies for AML, ALL, or MDS

What this Trial Is About

This research aims to monitor participants who previously received TSC-100 or TSC-101 T-cell receptor engineered T-cell TCR-T therapies in the TSCAN-001 study. The goal is to assess the long-term safety and efficacy of these investigational treatments over a 15-year period following their administration, focusing on people treated for conditions such as AML, ALL, and MDS. Participants will not receive any new study drug during this long-term follow-up study. Instead, they will be observed after completing the initial TSCAN-001 trial, while continuing any other cancer treatments as necessary. Monitoring will include a period lasting 15 years from the date of their original TCR-T cell therapy. During the study, participants will be evaluated for treatment-emergent adverse events to assess safety and tolerability. Researchers will also monitor overall survival, relapse-free survival, and progression-free survival over the 15 years. This observational study involves regular assessments to track long-term outcomes without administering additional investigational treatments.

A Long Term Follow-up Study of TScan TCR-T Products